Educational Needs for Physicians
Related Research units
Abstract
CAR-T cells are novel therapies associated with promising and potentially curative outcomes in patients with high-risk relapsed disease. In Europe, there are currently three approved products (tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel) for patients with acute lymphoblastic leukaemia, aggressive B-cell lymphoma, and mantle cell lymphoma, although expanded haematologic and nonhaematologic indications are expected soon.
Bibliographical data
| Original language | English |
|---|---|
| Title of host publication | The EBMT/EHA CAR-T Cell Handbook |
| Editors | Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele |
| REQUIRED books only: Number of pages | 4 |
| Place of Publication | Cham |
| Publisher | Springer International Publishing |
| Publication date | 2022 |
| Edition | 1 |
| Pages | 203-206 |
| ISBN (Print) | 978-3-030-94352-3 |
| ISBN (Electronic) | 978-3-030-94353-0 |
| DOIs | |
| Publication status | Published - 2022 |
